Is The Production Of New Coronavirus Vaccine Limited By Glass Bottle And Egg? Experts Say Production Capacity Is Not Limited And Virus Mutation Is Not Affected

The new coronavirus (NCV) epidemic has become the most urgent public health problem in the world. With the rapid development of NCV vaccine in various countries, the mass production of NCV vaccine has attracted much attention. At the same time, there are also opinions and reports that the production capacity of NCV vaccine may be limited by glass bottles and eggs for transportation.

In this regard, on July 13, a new coronavirus vaccine research and development enterprise, which has entered the clinical stage, told the 21st century economic news reporter: "it is not as strange as the Internet that" the supply of vaccine glass bottles is insufficient or billions of vaccines cannot be transported ". We have already considered the production capacity and glass bottles, and are prepared."

According to the reporter of the 21st century economic report, China's vaccine research and development is also accelerating, including China biology, Kangxi Nuo and Kexing biology, which have been making layout for the follow-up production capacity. Recently, it has become the first vaccine production base in Zhejiang Province.

At a recent forum, Yu Xuefeng, co-founder, chairman and chief executive officer of consinor biology, also said that due to the mature technology, enterprises can achieve large-scale production. "At the same time of the third phase of clinical treatment, we are also stepping up the construction of production capacity, which can provide tens of billions of drugs for the society in the near future."

Capacity will not be limited

Affected by the epidemic situation, the vaccine has been highly concerned, and the discussion on the new coronavirus vaccine has been continuous. In recent years, even if we have to develop a vaccine for chicken crowns, we need to use a vaccine to inactivate the chicken embryo. Another industry insiders said that the new coronavirus vaccine may be limited by the shortage of glass bottles.

According to the official wechat, the vaccine industry in China is in short supply According to the report that "the shortage of vaccine bottles will affect vaccine production", based on the observation and data of vaccine bottle industry, the China Vaccine Industry Association, after communicating with several benchmarking enterprises, believes that China has the industrial foundation for the production of high-quality vaccine bottles. According to incomplete statistics, the annual output can at least reach more than 8 billion, which can meet the demand of new crown vaccine production.

A person in charge of an enterprise developing a new inactivated coronavirus vaccine pointed out to the reporter of 21st century economic news that the vaccine production capacity was limited by glass bottles, which began to spread in March and April. However, according to the industry, several enterprises that have entered the clinical stage have relevant considerations and layout.

The 21st century economic reporter inquired about medicinal glass on the enterprise inspection platform. The results showed that as of July 13, 2575 domestic enterprises had produced related products, mainly in Guangdong, Shandong, Jiangsu and Zhejiang.

According to the introduction, the vaccine is generally water injection, the dose will not be too large, so the vaccine generally uses 1ml pre sealed syringe or 3ml (ISO 2R) vials. According to the production volume of several competitive manufacturers disclosed in the annual report of Shandong Pharmaceutical glass, the annual production capacity of several leading manufacturers of borosilicate bottles exceeds 20 billion. And there are many manufacturers that are not included in the statistics.

For the new coronavirus vaccine capacity limited by chicken embryos, in the view of vaccine expert Tao Lina, this view simply does not hold water.

Tao Lina pointed out that all the inactivated new coronal vaccines disclosed in China are made by culturing the virus in Vero cells, inactivating the virus after harvesting and adding adjuvants, so it is not necessary to culture the virus with chicken embryos.

Yu Xuefeng also said that due to the mature technology, enterprises can achieve large-scale production of adenovirus vector vaccine.

Active layout of enterprises

It is understood that many enterprises have been in the layout of new coronavirus vaccine mass production.

On July 11, the industrial base of emmerion virus vaccine was officially laid in Ningbo Free Trade Zone. It is understood that the total investment in the construction of the base is 2.5 billion yuan, and the project will be implemented in three phases, of which 1.3 billion yuan will be invested in the first phase to build the industrialization project of new crown vaccine, high-level biological laboratory and new human rabies vaccine.

At present, China biology, Kexing biology and kangxinuo are actively preparing for mass production. The batch production of the workshop of Beijing Institute of biological products of China is more than 3 million doses, and the annual production capacity will reach 100-120 million doses after mass production; the construction of the new crown inactivated vaccine workshop of Wuhan Institute of biological products is expected to be completed by the end of June and the beginning of July. Combined with the two research institutes of China biology, the annual production capacity can reach more than 200 million doses, ensuring the accessibility of the new crown inactivated vaccine.

In addition, according to the 21st century economic report, the reporter learned from Kexing biology that Kexing Zhongwei is building a new crown vaccine production workshop in Daxing District of Beijing, and it is expected to supply 100 million doses of new crown vaccine every year after it is put into operation. Connaught is also actively preparing for mass production.

Yuxuefeng pointed out that the current demand for vaccines is huge. The advantage of adenovirus vector vaccine can be intramuscular injection or even mucosal immunity, while inactivated vaccine can only be injected.

"According to China's demand of 100.2 billion doses, the plant we are building now can also achieve this goal. In the past, the vaccine scale was not so large because it was made for infants and young children. Now the situation is different, and the production capacity is not a problem." Yuxuefeng pointed out that the production capacity of 1 billion agents may be reached in the future.

In fact, some people worry that even if a new coronavirus vaccine is developed and mass-produced in the future, once the virus mutates or makes the vaccine ineffective.

For the virus mutation problem, yuxuefeng analysis said that this is a normal phenomenon, according to genetic principles, the probability of DNA base mutation is about one in a million.

Yuxuefeng takes the research and development of Ebola vaccine as an example. The protein previously used by moshadong was the original Ebola protein discovered in 1976. When they made the Ebola vaccine in 2014, they used the 2014 antigen. The two amino acid sequences are 3% different, but in fact, they are consistent in the protection effect.

"Therefore, our vaccine targets multiple targets and produces multiple antibodies. There will be no great difference in protection due to mutations in one site or several sites. Even if the changes do affect the efficacy of the vaccine, the function of genetic engineering vaccine as a viral vector is that it can cut out that gene and replace it in the disease vector, and the vaccine can be updated Feng Yu further analysis.

Chen Zhengming, Professor of epidemiology at Oxford University, fully agrees with the view of yuxuefeng, and points out that there are more than 500 kinds of vaccines. The worst thing is that combined drugs and combined immunization can provide more lasting effects. At present, the virus is relatively stable, and there should be no major problems in the near future.

?